{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:19:49Z","timestamp":1783441189206,"version":"3.54.6"},"reference-count":29,"publisher":"Bioscientifica","issue":"10","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":133,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>X-linked hypophosphatemia (XLH) is a rare disease caused by PHEX variants. Besides rickets, XLH leads to disproportionately short stature, which develops during the first months of life. Burosumab afforded minimal improvement of growth in children above the age of 4 years. No data are available on growth, including body mass index, of XLH children who started burosumab at a very young age, i.e., between 1 and 4 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a prospective follow-up of growth and other XLH-related outcomes in XLH children who started burosumab before the age of 4 years. We compared these children 1:2 with a historical cohort of XLH children who started vitamin D analogs and phosphate supplements before the age of 4 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 15 children treated with burosumab and 31 children treated with vitamin D analogs and phosphate supplements. In the burosumab-treated group, mean \u00b1 SD for age at therapy baseline was 2.1 \u00b1 0.7 years (range: 1\u20132.9 years). They were treated with oral phosphate and active vitamin D for 1.7 \u00b1 0.8 years before switching to burosumab. From birth to burosumab start, they presented a decline in height standard deviation score (SDS) from \u22120.3 \u00b1 0.7 to \u22121.4 \u00b1 0.8 (mean \u00b1 SD), respectively, P &amp;lt; 0.001. On burosumab, height SDS did not decline further during the first 2 years of treatment: mean \u00b1 SD 0.1 \u00b1 0.6 (range: \u22120.7\u20131.3 SDS) after 1 year (P = 0.16) and 0.0 \u00b1 0.7 SD (range: \u22120.6\u20131.4 SDS) after 2 years (P = 0.54). Burosumab did not correct the acquired height deficit, as children had a difference in height SDS of \u22121.5 SDS after 2 years of therapy when compared to birth length SDS (P = 0.04). BMI SDS did not significantly change during the first 2 years on burosumab. Children treated with vitamin D analogs and phosphate supplements started treatment at a mean \u00b1 SD age of 1.3 \u00b1 0.7 years (range: 0.1\u20133.0 years) and presented a continuous decline in height SDS of 0.7 \u00b1 0.9 SDS (range: \u22122.6\u20131) during the first 2 years of therapy (P &amp;lt; 0.001) and up to 4 years of age (\u22121.8 \u00b1 0.9 SDS to \u22121.9 \u00b1 0.9, respectively). BMI SDS increased by 0.5 \u00b1 0.9 SDS (range: \u22120.6\u20131.9) during the same period (P = 0.006).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We present data from the largest pediatric XLH cohort of very young children treated with burosumab over a follow-up period of 2 years. Our data suggest that, in contrast to the combination of vitamin D analogs and phosphate supplements, burosumab prevents further height deficit in XLH children, even at a period of life associated with high growth velocity. In addition, burosumab prevents the early and excessive weight gain associated with the development of XLH in children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance statement<\/jats:title>\n                    <jats:p>Most patients with X-linked hypophosphatemic rickets (XLH) present with short stature. This is the first large study on XLH children younger than 5 years treated with burosumab since a mean age of 2.1 years. We analyzed growth over a period of 2 years of therapy. Our data show that, in XLH toddlers, burosumab therapy prevents the further loss of height and the weight gain observed in patients treated with oral phosphate and active vitamin D therapy at the same age. As burosumab leads to better long-term outcomes in these children, we hope that our work will encourage the early use of burosumab and motivate further research in this field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/ec-25-0435","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:48:14Z","timestamp":1759250894000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":1,"title":["Burosumab prevents further height deficit in toddlers affected by XLH"],"prefix":"10.1530","volume":"14","author":[{"given":"Elisa","family":"Sala","sequence":"first","affiliation":[{"name":"AP HP, Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, Bic\u00eatre Paris-Saclay University Hospital 1 , ,","place":["Le Kremlin Bic\u00eatre, France"]},{"name":"AP HP, Reference Center for Rare Disorders of The Calcium and Phosphate Metabolism, Fili\u00e8re OSCAR and Platform of Expertise for Rare Diseases Paris-Saclay, EndoRare and BOND ERN, Bic\u00eatre Paris Saclay Hospital 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]},{"name":"Department of Endocrinology and Diabetology for Children, San Raffaele Hospital 3 , ,","place":["Milan, Italy"]},{"name":"University \u201cVita-Salute San Raffaele\u201d 4 , ,","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jugurtha","family":"Berkenou","sequence":"additional","affiliation":[{"name":"AP HP, Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, Bic\u00eatre Paris-Saclay University Hospital 1 , ,","place":["Le Kremlin Bic\u00eatre, France"]},{"name":"AP HP, Reference Center for Rare Disorders of The Calcium and Phosphate Metabolism, Fili\u00e8re OSCAR and Platform of Expertise for Rare Diseases Paris-Saclay, EndoRare and BOND ERN, Bic\u00eatre Paris Saclay Hospital 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rothenbuhler","sequence":"additional","affiliation":[{"name":"AP HP, Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, Bic\u00eatre Paris-Saclay University Hospital 1 , ,","place":["Le Kremlin Bic\u00eatre, France"]},{"name":"AP HP, Reference Center for Rare Disorders of The Calcium and Phosphate Metabolism, Fili\u00e8re OSCAR and Platform of Expertise for Rare Diseases Paris-Saclay, EndoRare and BOND ERN, Bic\u00eatre Paris Saclay Hospital 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4232-3882","authenticated-orcid":true,"given":"Anne-Sophie","family":"Lambert","sequence":"additional","affiliation":[{"name":"AP HP, Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, Bic\u00eatre Paris-Saclay University Hospital 1 , ,","place":["Le Kremlin Bic\u00eatre, France"]},{"name":"AP HP, Reference Center for Rare Disorders of The Calcium and Phosphate Metabolism, Fili\u00e8re OSCAR and Platform of Expertise for Rare Diseases Paris-Saclay, EndoRare and BOND ERN, Bic\u00eatre Paris Saclay Hospital 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]},{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes 5 , ,","place":["Le Kremlin-Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Audrain","sequence":"additional","affiliation":[{"name":"AP HP, Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, Bic\u00eatre Paris-Saclay University Hospital 1 , ,","place":["Le Kremlin Bic\u00eatre, France"]},{"name":"AP HP, Reference Center for Rare Disorders of The Calcium and Phosphate Metabolism, Fili\u00e8re OSCAR and Platform of Expertise for Rare Diseases Paris-Saclay, EndoRare and BOND ERN, Bic\u00eatre Paris Saclay Hospital 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Girerd","sequence":"additional","affiliation":[{"name":"AP HP, Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, Bic\u00eatre Paris-Saclay University Hospital 1 , ,","place":["Le Kremlin Bic\u00eatre, France"]},{"name":"AP HP, Reference Center for Rare Disorders of The Calcium and Phosphate Metabolism, Fili\u00e8re OSCAR and Platform of Expertise for Rare Diseases Paris-Saclay, EndoRare and BOND ERN, Bic\u00eatre Paris Saclay Hospital 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pitea","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology for Children, San Raffaele Hospital 3 , ,","place":["Milan, Italy"]},{"name":"University \u201cVita-Salute San Raffaele\u201d 4 , ,","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mora","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology for Children, San Raffaele Hospital 3 , ,","place":["Milan, Italy"]},{"name":"University \u201cVita-Salute San Raffaele\u201d 4 , ,","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[{"name":"AP HP, Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, Bic\u00eatre Paris-Saclay University Hospital 1 , ,","place":["Le Kremlin Bic\u00eatre, France"]},{"name":"AP HP, Reference Center for Rare Disorders of The Calcium and Phosphate Metabolism, Fili\u00e8re OSCAR and Platform of Expertise for Rare Diseases Paris-Saclay, EndoRare and BOND ERN, Bic\u00eatre Paris Saclay Hospital 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]},{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes 5 , ,","place":["Le Kremlin-Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-0975","authenticated-orcid":true,"given":"Diana-Alexandra","family":"Ertl","sequence":"additional","affiliation":[{"name":"AP HP, Department of Endocrinology and Diabetology for Children and Department of Adolescent Medicine, Bic\u00eatre Paris-Saclay University Hospital 1 , ,","place":["Le Kremlin Bic\u00eatre, France"]},{"name":"AP HP, Reference Center for Rare Disorders of The Calcium and Phosphate Metabolism, Fili\u00e8re OSCAR and Platform of Expertise for Rare Diseases Paris-Saclay, EndoRare and BOND ERN, Bic\u00eatre Paris Saclay Hospital 2 , ,","place":["Le Kremlin-Bic\u00eatre, France"]},{"name":"Universit\u00e9 Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes 5 , ,","place":["Le Kremlin-Bic\u00eatre, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2026070711003022700_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2026070711003022700_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","article-title":"Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia","volume":"18","author":"Trombetti","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"2026070711003022700_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s00223-023-01092-1","article-title":"Fibroblast growth factor 23 bone regulation and downstream hormonal activity","volume":"113","author":"Clinkenbeard","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"2026070711003022700_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11914-021-00703-w","article-title":"Regulation of FGF23: beyond bone","volume":"19","author":"Simic","year":"2021","journal-title":"Curr Osteoporos Rep"},{"key":"2026070711003022700_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"2026070711003022700_bib6","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2026070711003022700_bib7","article-title":"Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH)","volume":"103S","author":"Rothenbuhler","year":"2020","journal-title":"Metabolism"},{"key":"2026070711003022700_bib8","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1210\/clinem\/dgaa495","article-title":"Growth curves for children with X-linked hypophosphatemia","volume":"105","author":"Mao","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711003022700_bib9","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-Linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"2026070711003022700_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jbmr.275","article-title":"Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice","volume":"26","author":"Aono","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2026070711003022700_bib11","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"2026070711003022700_bib12","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"2026070711003022700_bib13","doi-asserted-by":"crossref","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","article-title":"Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia","volume":"107","author":"Ward","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711003022700_bib14","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of Burosumab, a monoclonal antibody to FGF23, in children with X-Linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711003022700_bib15","doi-asserted-by":"crossref","first-page":"e998","DOI":"10.1210\/clinem\/dgad223","article-title":"Effects of burosumab treatment on mineral metabolism in children and adolescents with X-linked hypophosphatemia","volume":"108","author":"Ewert","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711003022700_bib16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s13023-022-02562-9","article-title":"Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone","volume":"17","author":"Ertl","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026070711003022700_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2021.105208","article-title":"X-linked hypophosphatemia and burosumab: practical clinical points from the French experience","volume":"88","author":"Bacchetta","year":"2021","journal-title":"Jt Bone Spine"},{"key":"2026070711003022700_bib19","first-page":"839","article-title":"Effects of calcitriol and phosphorus therapy on the growth of patients with X-linked hypophosphatemia","volume":"76","author":"Friedman","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711003022700_bib20","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2003-030036","article-title":"Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets","volume":"88","author":"M\u00e4kitie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070711003022700_bib21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s13023-022-02590-5","article-title":"Growth hormone treatment improves final height in children with X-linked hypophosphatemia","volume":"17","author":"Andr\u00e9","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"2026070711003022700_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/ejendo\/lvad144","article-title":"Adult height improved over decades in patients with X-linked hypophosphatemia: a cohort study","volume":"189","author":"Boros","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026070711003022700_bib23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/adc.58.12.1020","article-title":"Early treatment of familial hypophosphataemic rickets","volume":"58","author":"Roza","year":"1983","journal-title":"Arch Dis Child"},{"key":"2026070711003022700_bib24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s004310050962","article-title":"Calcium metabolism and growth during early treatment of children with X-linked hypophosphataemic rickets","volume":"157","author":"Kruse","year":"1998","journal-title":"Eur J Pediatr"},{"key":"2026070711003022700_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S2213-8587(18)30338-3","article-title":"Efficacy and safety of burosumab in children aged 1\u20134 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070711003022700_bib26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1530\/EC-19-0481","article-title":"Increased prevalence of overweight and obesity in children with X-linked hypophosphatemia","volume":"9","author":"Zhukouskaya","year":"2020","journal-title":"Endocr Connect"},{"key":"2026070711003022700_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1034580","article-title":"Burosumab for X-linked hypophosphatemia in children and adolescents: opinion based on early experience in seven European countries","volume":"13","author":"Mughal","year":"2023","journal-title":"Front Endocrinol"},{"key":"2026070711003022700_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.688309","article-title":"X-Linked hypophosphatemic rickets: multisystemic disorder in children requiring multidisciplinary management","volume":"12","author":"Baroncelli","year":"2021","journal-title":"Front Endocrinol"},{"key":"2026070711003022700_bib29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/MNH.0b013e3282fd6e5b","article-title":"PHEX, FGF23, DMP1 and beyond","volume":"17","author":"Strom","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026070711003022700_bib30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jbspin.2019.01.012","article-title":"X-linked hypophosphatemia: management and treatment prospects","volume":"86","author":"Lambert","year":"2019","journal-title":"Jt Bone Spine"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/14\/10\/EC-25-0435.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/14\/10\/EC-25-0435.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0435\/9751\/ec-25-0435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/doi\/10.1530\/EC-25-0435\/9751\/ec-25-0435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:31:43Z","timestamp":1783438303000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/14\/10\/e250435\/1428\/Burosumab-prevents-further-height-deficit-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-25-0435","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"article-number":"e250435"}}